A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Ningbo Medical Center Lihuili Hospital
Astellas Pharma Inc
Taiho Oncology, Inc.
NRG Oncology
UNC Lineberger Comprehensive Cancer Center
Ruijin Hospital
Yale University
Medical College of Wisconsin
Baylor Research Institute
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Mayo Clinic
Bold Therapeutics, Inc.
National Health Research Institutes, Taiwan
UNC Lineberger Comprehensive Cancer Center
IMGT Co., Ltd.
Medical College of Wisconsin
National Health Research Institutes, Taiwan
Tyligand Pharmaceuticals (Suzhou) Limited
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
Georgetown University
Thomas Jefferson University
University of Nebraska
University of Cincinnati
DEKA Biosciences
Gruppo Oncologico del Nord-Ovest
Second Affiliated Hospital, School of Medicine, Zhejiang University
Thomas Jefferson University
ImmunityBio, Inc.
CNAO National Center of Oncological Hadrontherapy
Ono Pharmaceutical Co., Ltd.
Case Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
The First Affiliated Hospital with Nanjing Medical University
Ohio State University Comprehensive Cancer Center
University of Kansas Medical Center
Dana-Farber Cancer Institute
Akeso
ImmunityBio, Inc.
Bruckner Oncology
Australasian Gastro-Intestinal Trials Group
Oslo University Hospital
Eli Lilly and Company
Ono Pharmaceutical Co., Ltd.
Erasmus Medical Center
ImmunityBio, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.